Purple Biotech Director Holds 3 M Shares, Vests Multi‑Million Options Amid 79% Stock Slide【News Flash】
Explore how Purple Biotech’s insider stake and low‑price options impact investors and future growth prospects.
3 minutes to read
Purple Biotech Ltd
Purple Biotech CEO’s Massive Insider Stakes Signal Bold Confidence Amid 80% Stock Decline
Insider holdings show CEO Gil’s confidence in Purple Biotech’s niche drug prospects, yet the low share price and heavy option use warn investors to watch clinical milestones.
2 minutes to read
Purple Biotech Insider Deals: CEO’s Deep‑Discount Options Stir Investor Alarm as AI‑Driven Antibody Push Looms
Insider activity at Purple Biotech shows Lankry Shai’s huge discounted stock options and RSUs, highlighting potential dilution, growth incentives, and AI‑driven antibody strategy.
3 minutes to read